A Study to Evaluate Skin Irritation and Photo Irritation of JNJ 10229570-AAA on Intact Skin of Japanese Healthy Male Participants
Study Details
Study Description
Brief Summary
The purpose of this study is to evaluate skin irritation and photo irritation of JNJ 10229570-AAA on intact skin of Japanese healthy male participants.
| Condition or Disease | Intervention/Treatment | Phase |
|---|---|---|
|
Phase 1 |
Detailed Description
This is a single center, interpreter-blinded (the person interpreting the results does not know the name of the assigned drug), randomized (drug is assigned by chance like flipping a coin), vehicle-controlled, closed-patch test study. Thirty (30) Japanese participants will be enrolled in the study. Each treatment (JNJ 10229570-AAA at 1.2%, 2.4%, 3.6%, vehicle in a cream formulation, and petroleum jelly) will be randomly applied in vertical position on the back of each participant, with a corresponding strength applied at the same vertical position (left vs. right). The study drugs applied on the left side will be washed off at 48 hours after application. The dermatological evaluation and photo shoots will be done at 1 (T49) and 24 (T72) hours after washing off the drugs. All participants who completed the dermatological evaluation will be included in the evaluation of skin irritation and skin photo irritation. The study drugs applied on the right side will be washed off at 24 hours after application. The dermatological evaluation and photo shoots will be done at 1 hour after washing off. Ultraviolet A (UVA) will be irradiated to the application site. One hour after irradiation start (T26), the dermatological evaluation and photo shoots will be done. Afterwards the application site will be covered for the protection against UV. Twenty-four hours after washing off (T48), the cover will be taken off, and then the dermatological evaluation and photo shoots will be done at 1 (T49) and 24 (T72) hours. Additionally, the safety profile of JNJ 10229570-AAA will be assessed during the study. The study has a total duration of maximum 32 days.
Study Design
Arms and Interventions
| Arm | Intervention/Treatment |
|---|---|
| Experimental: Closed-patch test
|
Drug: JNJ 10229570-AAA 1.2% cream
A patch containing the cream will be applied on the back and left for 48 hours on the left side, and 24 hours on the right side.
Drug: JNJ 10229570-AAA 2.4% cream
A patch containing the cream will be applied on the back and left for 48 hours on the left side, and 24 hours on the right side.
Drug: JNJ 10229570-AAA 3.6% cream
A patch containing the cream will be applied on the back and left for 48 hours on the left side, and 24 hours on the right side.
Drug: Color-matched vehicle in a cream formulation containing 0 mg of JNJ 10229570-AAA
A patch containing the cream will be applied on the back and left for 48 hours on the left side, and 24 hours on the right side.
Drug: Petroleum jelly
A patch containing the petroleum jelly will be applied on the back and left for 48 hours on the left side, and 24 hours on the right side.
|
Outcome Measures
Primary Outcome Measures
- Skin irritation according to the Japanese evaluation criteria (scores on a scale) [72 hours]
The Japanese skin irritation evaluation criteria is a 6-point scale specifying the irritation level of the skin, from 0 (no response) to 4 (blister)
- Skin photo irritation according to the Japanese evaluation criteria (scores on a scale) [72 hours]
The Japanese skin photo irritation evaluation criteria is a 6-point scale specifying the level of skin photo irritation from 0 (lack of reaction or reaction comparable to non-irradiated site) to 4 (reaction four ranks more pronouced using domestic criteria compared with non-irradiated site)
Secondary Outcome Measures
- Skin irritation according to the International Contact Dermatitis Research Group (ICDRG) criteria (measurements on a scale) [72 hours]
The ICDRG scale measures the level of skin irritation from Negative (no reaction) to Extreme Positive Reaction (erythema, infiltration, confluent vesicles)
- Skin photo irritation according to the International Contact Dermatitis Research Group (ICDRG) criteria (measurements on a scale) [72 hours]
The ICDRG scale measures the level of skin irritation from Negative (no reaction) to Extreme Positive Reaction (erythema, infiltration, confluent vesicles)
- Number of participants with adverse events as a measure of safety and tolerability [32 days]
Eligibility Criteria
Criteria
Inclusion Criteria:
-
Signed an informed consent document
-
Body mass index between 18.0 and 30.0 kg/m2 (inclusive), and body weight not less than 50 kg
-
Blood pressure between 90 and 140 mmHg systolic (inclusive), and no higher than 90 mmHg diastolic
-
Electrocardiogram (ECG) consistent with normal cardiac conduction and function
-
Non-smoker
-
Agree to use an adequate contraception method
Exclusion Criteria:
-
History of or current clinically significant medical illness that the investigator considers should exclude the participant or that could interfere with the interpretation of the study results
-
Clinically significant abnormal values for hematology, biochemistry or urinalysis
-
Clinically significant abnormal physical examination, vital signs or ECG
-
Use of any prescription or nonprescription medication (including vitamins and herbal supplements) within 14 days before the study treatment
-
History of drug or alcohol abuse within the past 5 years
-
Drug allergy or drug hypersensitivity
-
Blood donation, depending on the volume of blood collection
-
Positive test for human immunodeficiency virus (HIV), hepatitis B or C, or syphilis
-
Dermatological disease at application site
-
Photosensitivity
-
Exposure to excessive or chronic ultraviolet (UV) radiation (i.e., sunbathing, tanning salon use, phototherapy) within 4 weeks prior to study treatment or planned during the study period
Contacts and Locations
Locations
| Site | City | State | Country | Postal Code | |
|---|---|---|---|---|---|
| 1 | Fukukoka | Japan | |||
| 2 | Hakata | Japan |
Sponsors and Collaborators
- Janssen Pharmaceutical K.K.
Investigators
- Study Director: Janssen Pharmaceutical K.K., Japan Clinical Trial, Janssen Pharmaceutical K.K.
Study Documents (Full-Text)
None provided.More Information
Publications
None provided.- CR018670
- 10229570-JPN-01